X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with Elder Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs ELDER PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA ELDER PHARMA SHASUN PHARMA/
ELDER PHARMA
 
P/E (TTM) x 123.9 -0.2 - View Chart
P/BV x 8.5 0.1 8,455.4% View Chart
Dividend Yield % 0.2 0.0 -  

Financials

 SHASUN PHARMA   ELDER PHARMA
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
ELDER PHARMA
Jun-14
SHASUN PHARMA/
ELDER PHARMA
5-Yr Chart
Click to enlarge
High Rs94380 24.8%   
Low Rs46188 24.3%   
Sales per share (Unadj.) Rs214.2491.2 43.6%  
Earnings per share (Unadj.) Rs5.3-3.2 -167.7%  
Cash flow per share (Unadj.) Rs15.814.4 109.8%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %1.40-  
Book value per share (Unadj.) Rs53.3376.5 14.2%  
Shares outstanding (eoy) m56.6220.54 275.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.30.6 56.4%   
Avg P/E ratio x13.1-89.3 -14.7%  
P/CF ratio (eoy) x4.419.7 22.4%  
Price / Book Value ratio x1.30.8 173.7%  
Dividend payout %18.70-   
Avg Mkt Cap Rs m3,9585,833 67.8%   
No. of employees `000NANA-   
Total wages/salary Rs m2,1642,179 99.3%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m12,12710,089 120.2%  
Other income Rs m229257 89.4%   
Total revenues Rs m12,35610,346 119.4%   
Gross profit Rs m1,009-792 -127.4%  
Depreciation Rs m594361 164.3%   
Interest Rs m4152,756 15.1%   
Profit before tax Rs m230-3,653 -6.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m03,713 0.0%   
Tax Rs m-73125 -58.1%   
Profit after tax Rs m302-65 -462.3%  
Gross profit margin %8.3-7.8 -106.0%  
Effective tax rate %-31.7-3.4 924.1%   
Net profit margin %2.5-0.6 -384.6%  
BALANCE SHEET DATA
Current assets Rs m6,8849,240 74.5%   
Current liabilities Rs m8,4569,998 84.6%   
Net working cap to sales %-13.0-7.5 172.6%  
Current ratio x0.80.9 88.1%  
Inventory Days Days6246 133.1%  
Debtors Days Days10860 179.4%  
Net fixed assets Rs m4,97010,124 49.1%   
Share capital Rs m113206 55.1%   
"Free" reserves Rs m2,8755,582 51.5%   
Net worth Rs m3,0207,734 39.1%   
Long term debt Rs m1,8174,889 37.2%   
Total assets Rs m13,34722,882 58.3%  
Interest coverage x1.6-0.3 -477.5%   
Debt to equity ratio x0.60.6 95.2%  
Sales to assets ratio x0.90.4 206.1%   
Return on assets %5.411.8 45.7%  
Return on equity %10.0-0.8 -1,183.8%  
Return on capital %13.322.3 59.7%  
Exports to sales %46.43.0 1,525.4%   
Imports to sales %14.20.4 3,335.0%   
Exports (fob) Rs m5,622307 1,833.5%   
Imports (cif) Rs m1,72843 4,008.6%   
Fx inflow Rs m5,843307 1,905.6%   
Fx outflow Rs m2,173125 1,734.3%   
Net fx Rs m3,669181 2,024.0%   
CASH FLOW
From Operations Rs m39811,754 3.4%  
From Investments Rs m-1,635-561 291.7%  
From Financial Activity Rs m1,309-6,762 -19.4%  
Net Cashflow Rs m714,432 1.6%  

Share Holding

Indian Promoters % 39.2 39.6 99.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.6 7.5 48.0%  
FIIs % 17.6 16.8 104.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 36.1 109.7%  
Shareholders   20,750 16,479 125.9%  
Pledged promoter(s) holding % 12.3 77.6 15.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   PFIZER  GSK PHARMA  PANACEA BIOTECH  WYETH LTD  ABBOTT INDIA  

Compare SHASUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Lower; Vedanta & Kotak Mahindra Top Losers(Closing)

Indian share markets ended marginally lower on Monday amid weak global cues. The BSE Metal index, however, lost 1.7 amid rising global trade war fears.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 8-QTR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS